Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €15.21 EUR
Change Today +0.427 / 2.89%
Volume 0.0
DY8 On Other Exchanges
Symbol
Exchange
NASDAQ GM
Frankfurt
As of 1:40 PM 03/27/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

Gustav A. Christensen

Chief Executive Officer, President and Director, Dyax Corp.
AgeTotal Calculated CompensationThis person is connected to 16 board members in 3 different organizations across 5 different industries.

See Board Relationships
66$1,690,001
As of Fiscal Year 2013

Background*

Mr. Gustav A. Christensen has been Chief Executive Officer and President of Dyax Corp. since January 1, 2009. Mr. Christensen serves as Chief Executive Officer and Chairman of the United States Office at affentranger associates sa, Investment arm. Mr. Christensen joined Dyax in April 2007. He has been Chief Executive Officer of Phylos, Inc. since August 2000. He served as Managing Director of Apeiron Partners, LLC, a boutique life sciences investment bank, from 2005 ...

Read Full Background

Corporate Headquarters*

55 Network Drive
Burlington, Massachusetts 01803

United States

Phone: 617-225-2500
Fax: 617-225-2501

Board Members Memberships*

Former Director
Former Director
1990-N/A
Former Director
1990-Present
Chairman of the Board
2008-Present
Chief Executive Officer, President and Director

Education*

MBA
Harvard Business School
MS
Aarhus Universitet

Other Affiliations*

Annual Compensation*

Salary$583,495
Bonus$32,092
Total Annual Compensation$615,587

Stock Options*

All Other Compensation$10,898
Exercisable Options895,833
Unexercisable Options1,497,622
Total Number of Options2,393,455

Total Compensation*

Total Annual Cash Compensation$931,361
Total Short Term Compensation$615,587
Other Long Term Compensation$10,898
Total Calculated Compensation$1,690,001
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DY8:GR €15.21 EUR +0.427

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Jon P. Stonehouse Chief Executive Officer, President and Executive Director
BioCryst Pharmaceuticals, Inc.
$475.7K
Leonard S. Schleifer M.D., Ph.D.Co-Founder, Chief Executive Officer, President, Executive Director and Ex Officio Member of Technology Committee
Regeneron Pharmaceuticals, Inc.
$3.1M
Flemming Ornskov M.D., MBA, MPHChief Executive Officer, Managing Director and Director
Shire plc
$3.6M
Thomas W. D'Alonzo Esq., J.D.Chairman, Acting Chief Executive Officer, Acting President, Member of Audit Committee, Member of Nominating/Corporate Governance Committee and Member of Compensation Committee
Salix Pharmaceuticals Ltd.
--
Compensation as of Fiscal Year 2013.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DYAX CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.